Astragalus, a traditional Chinese root taken as a supplement for energy and resistance to illness, shows modest benefits mainly in people with disease: lower long-term blood sugar in type 2 diabetes and less fatigue. No study has shown longer life in people. Side effects were mild; the main concerns are interference with anti-rejection drugs, possible worsening of autoimmune disease and the unresolved question of cancer risk. (Full Review)

Protocol

Whole root (decoction or granules)

15 g daily

Raw-herb equivalent as granules for 48 weeks; traditional Dang-gui buxue tang uses 30 g root with 6 g Angelica sinensis root

Root capsules or extract

500 mg root extract twice daily

Or 2.8 g root preparation three times daily, or 480 mg standardized extract daily as two 240 mg capsules

Isolated compounds

Astragaloside IV 5–10 mg daily

TA-65 16 mg or 250 units, once daily

Time to effect

Fatigue

Within 4 weeks

Reduced fatigue with an oral root preparation

Kidney function

Over 48 weeks

Slower loss of kidney filtering capacity with oral granules in diabetic kidney disease

Knee pain

Within 5 days

Less pain with a standardized root extract in a single trial

Benefits

High: Lower blood glucose in type 2 diabetes; reduced fatigue

Medium: Slower kidney function decline in diabetic kidney disease; lower blood pressure; better functional recovery after stroke; reduced knee joint pain

Low: Better heart function in chronic heart failure; longer survival alongside platinum chemotherapy; fewer chemotherapy side effects; less radiation-induced lung injury; relief of seasonal allergic rhinitis; lower blood cholesterol; less heart-muscle injury in viral myocarditis; fewer flare-ups in stable chronic obstructive pulmonary disease; better blood counts in aplastic anemia; less nerve damage in diabetic peripheral neuropathy; better vision in diabetic retinopathy; fewer respiratory infections; less neck and arm pain in cervical radiculopathy; better lung function in idiopathic pulmonary fibrosis; fewer relapses of cough-variant asthma; better endoscopic healing in chronic gastritis; faster recovery in acute pancreatitis; better liver function in cirrhosis

Speculative: Telomere lengthening; immune modulation; longer healthspan and lifespan; protection of cognition

Contraindications

People with autoimmune diseases (e.g., lupus, rheumatoid arthritis)

Organ transplant recipients taking calcineurin inhibitors (tacrolimus, cyclosporine) or other immunosuppressants

Pregnant or breastfeeding women (inferred; no human data)

For telomerase activators (TA-65, cycloastragenol): people with active cancer, a cancer history, or known telomere-lengthening germline variants such as POT1 mutations (inferred; no human data on the supplements)

Key Interactions

Tacrolimus (and other calcineurin inhibitors, anti-rejection drugs such as cyclosporine)

Glucose-lowering drugs (metformin, sulfonylureas such as gliclazide, insulin)

Blood pressure drugs (ACE inhibitors such as enalapril; angiotensin receptor blockers such as losartan)

Fexofenadine (a P-glycoprotein substrate) in ABCB1 3435CC carriers

Theoretical (inferred from mechanism)

Drugs cleared by the liver enzyme CYP2D6 (metoprolol, codeine)

Drugs cleared by the liver enzyme CYP3A4 (atorvastatin, over-the-counter omeprazole)

Immunosuppressive drugs (mycophenolate, prednisone)

Lithium

Immune-stimulating supplements (echinacea, beta-glucans)

Glucose- or blood-pressure-lowering supplements (berberine, garlic)

Vaccination

Risk & Side Effects

Low: Mild gastrointestinal upset; loss of immunosuppressant drug effect; rash and transient liver test changes; cancer promotion by telomerase activation

Speculative: Worsening of autoimmune disease; harm to the fetus; poisoning from misidentified species

Monitoring

Marker	Target	Why
eGFR and serum creatinine	Creatinine 0.6–1.3 mg/dL; eGFR above 60 mL/min/1.73 m²	Kidney benefit; safety check
HbA1c	4.0–5.6%	Lower glucose
Fasting glucose	70–99 mg/dL	Safety check: additive lowering on diabetes drugs
ALT and AST	ALT 7–56 U/L; AST 10–40 U/L	Safety check: liver strain
Absolute lymphocyte count	1.0–4.8 × 10⁹/L	Immune effect of TA-65
hsCRP	No established target; track change from own baseline	Inflammation
Tacrolimus or cyclosporine trough level	No established target; track the range set by the transplant team	Safety check: level can fall
Leukocyte telomere length	No established target; track change from own baseline	TA-65 effect
Home blood pressure	Not specified in the ER	Safety check: additive lowering

Cadence: Baseline panel before starting; home blood pressure and, on glucose-lowering drugs, fasting glucose during weeks 1–4; repeat panel at 3 months, then every 6–12 months while use continues; telomere length, if measured, no sooner than 12 months

Qualitative Assessment

Energy and fatigue, ideally scored with a simple 0–10 daily rating or the Brief Fatigue Inventory
Frequency and duration of colds and other infections
Joint pain during walking or stair climbing
Digestive comfort, skin rashes and any joint or autoimmune symptoms
Light-headedness on standing, as a sign of additive blood pressure lowering

Astragalus for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment